The absence of molecular amplification in proteomics and metabolomics means that researchers rely heavily on sensitive detection of a biomarker during analytical separation. In recent years, LC performance has been the limiting factor in such experiments as the incremental improvement of conventional columns stalls. Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility, and robustness. PharmaFluidics’ game-changing micro-chip based chromatography columns, with unprecedented analytical resolution performance, are now being used for cutting-edge bio-marker, diagnostics, and drug research & development applications in the global biotech and pharma industries. The first µPAC™ columns were launched in 2017, and the company continues to build its portfolio based on the pillar array technology. With offices in Ghent, PharmaFluidics is located at the heart of the Flanders life sciences valley. This biotech hub features a mix of world-renowned universities, knowledge centers, and biotech companies, giving the company direct access to talent, financing opportunities and a network of thriving companies.